Select your Market
{{ userContent.title }}
Results of Q2 2022
Forecast for fiscal 2022
| Q2 2022 (in € billion) | Change (in %, compared to Q2 2021) | Organic growth (in %, compared to Q2 2021) | |
|---|---|---|---|
Group net sales: | 5.6 | 14.3 | 6.6 |
EBITDA pre: | 1.8 | 13.1 | 3.2 |
Life Science sales: | 2.6 | 19.0 | 10.4 |
Healthcare sales: | 1.9 | 7.6 | 1.4 |
Electronics sales: | € 996 million | 16.3 | 7.4 |
Q2 2022 underlines the resilience of our strategy to generate growth and with that, value for our patients and customers.
Overview by CFO Marcus Kuhnert.
Detailed information about our business in the first half of 2022.
Downloads for the Media
Additional Downloads
Press Releases
Merck KGaA, Darmstadt, Germany, continued its growth trajectory in the second quarter of 2022 despite a challenging environment. Net sales increased by 14.3% compared with the second quarter of 2021 to ...
2022/08/04
